Visit COVID-19 resources

[Skip to Content]

Certification figures and their accuracy – (Eye 29, 1516 (November 2015))

Nov 12
2015

Certification figures and their accuracy Eye 29, 1516 (November 2015). doi:10.1038/eye.2015.143 Authors: A Quartilho, A Zekite, W Xing, M Loutfi, C Bunce & R Wormald

  • 12 November 2015

The stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocity – (Eye 29, 1416 (November 2015))

Nov 12
2015

The stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocity Eye 29, 1416 (November 2015). doi:10.1038/eye.2015.140 Author: D Kent

  • 12 November 2015

High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population – (Eye 29, 1427 (November 2015))

Nov 12
2015

High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population Eye 29, 1427 (November 2015). doi:10.1038/eye.2015.150 Authors: D M Marcus, H Singh, C M Fechter & D P Chamberlain

  • 12 November 2015

Stability and safety of MA50 intraocular lens placed in the sulcus – (Eye 29, 1438 (November 2015))

Nov 12
2015

Stability and safety of MA50 intraocular lens placed in the sulcus Eye 29, 1438 (November 2015). doi:10.1038/eye.2015.105 Authors: P S Kemp & T A Oetting

  • 12 November 2015

Evaluating digital diabetic retinopathy screening in people aged 90 years and over – (Eye 29, 1442 (November 2015))

Nov 12
2015

Evaluating digital diabetic retinopathy screening in people aged 90 years and over Eye 29, 1442 (November 2015). doi:10.1038/eye.2015.130 Authors: A Tye, H Wharton, A Wright, Y Yang, J Gibson, A Syed, A Mills & P Dodson

  • 12 November 2015